05:07 AM EDT, 08/14/2026 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Thursday it launched a secondary public offering of 5 million common shares by selling stockholder KKR Genetic Disorder L.P.

BridgeBio will not sell any stock or receive any proceeds from the transaction, the company said.

The shares are being offered under BridgeBio's existing automatic shelf registration statement on Form S-3ASR, which became effective July 24, 2026.

The final terms of the offering will be disclosed in a prospectus supplement to be filed with the SEC.